Young adults with myopia who attend school may benefit from lower concentration atropine, which minimizes visual performance disruptions.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

The FDA has accepted for review the New Drug Application for SYD-101 (atropine sulfate) to slow the progression of myopia in children.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of myopia in children. Considered a common ...

Myopia treatments include orthokeratology lenses and low-dose atropine, each with potential side effects. A case study revealed esotropia as a possible complication of atropine use in myopia ...

The National Registry of Emergency Medical Technicians is America’s EMS certification organization – here’s how it works ...

In December, the U.S.-based National Academy of Sciences published a report classifying myopia, for the first time, as a ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

The following is a summary of “Sex dependent effects of cardiovascular agents on hemoglobin oxygen affinity – An ex-vivo experiment,” published in the February 2025 issue of Journal of Critical Care ...

As the use of smartphones and other digital devices increases, more children are experiencing deteriorating vision.

本文研究中，研究人员识别出了一种特殊的神经免疫回路，其中在急性病毒感染期间神经元会通过产生神经肽CGRP来参与T细胞的命运决策。 研究团队 ...